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A General Approach for the Site-Selective Modification of Native 
Proteins, Enabling the Generation of Stable and Functional 
Antibody-Drug Conjugates
Stephen J. Walsh,a Soleilmane Omarjee,b Warren R. J. D. Galloway,a Terence T.-L. Kwan,a Hannah 
F. Sore,a Jeremy S. Parker,c Marko Hyvönen,d Jason S. Carroll,b* David R. Springa*
Antibody-drug conjugates (ADCs) are a class of targeted therapeutics that utilize the specificity of antibodies to selectively 
deliver highly potent cytotoxins to target cells. Although recent years have witnessed significant interest in ADCs, problems 
remain with the standard linkage chemistries used for cytotoxin-antibody bioconjugation. These typically 1) generate 
unstable constructs, which may lead to premature cytotoxin release, 2) often give a wide variance in drug-antibody ratios 
(DAR) and 3) have poor control of attachment location on the antibody, resulting in a variable pharmacokinetic profile. 
Herein, we report a novel divinylpyrimidine (DVP) linker platform for selective bioconjugation via covalent re-bridging of 
reduced disulfide bonds on native antibodies. Model studies using the non-engineered trastuzumab antibody validate the 
utility of this linker platform for the generic generation of highly plasma-stable and functional antibody constructs that 
incorporate variable biologically relevant payloads (including cytotoxins) in an efficient and site-selective manner with 
precise control over DAR. DVP linkers were also used to efficiently re-bridge both monomeric and dimeric protein systems, 
demonstrating their potential utility for general protein modification, protein stabilisation or the development of other 
protein-conjugate therapeutics.
Introduction
The emergence of biotherapeutics in recent decades has 
opened up vast new areas of research for the treatment of a 
range of grievous diseases,1,2 with antibody-drug conjugates 
(ADCs) demonstrating considerable promise as anticancer 
agents.3,4 ADCs utilize the impeccable cell-targeting ability of 
an antibody in combination with the highly potent nature of a 
cytotoxic payload to achieve cell-selective cytotoxicity5 while 
overcoming the dose-limiting toxicity of classical non-targeted 
small molecule chemotherapy.6,7 There are currently four ADCs 
on the market8–11 and over 60 other ADCs in clinical trials.12 
However, current approaches for ADC production still have 
numerous shortcomings. Stability, drug-antibody ratio (DAR) 
and drug distribution have all been shown to be crucial to the 
efficacy, safety and overall pharmacological profile of ADCs 
and are strongly influenced by the chemistry used to attach 
the linker to the antibody. Commonly employed nucleophilic 
bioconjugation at cysteine or lysine residues are pseudorandom: in theory, any of the targeted amino acids 
within the antibody can be modified. Consequently, there is a 
lack of selectivity, leading to the formation of ADCs which are 
heterogeneous in terms of the number of cytotoxin molecules 
incorporated (the DAR) and their locations on the antibody. 
Such constructs are associated with unreliable 
pharmacokinetic profiles and therefore, a reduced 
pharmacological effect.13–17 Maleimide conjugation to reduced 
antibody cysteine thiols has been extensively used in ADC 
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Figure 1: a) Previous work using monovinylpyridine or maleimide linkers for the 
generation of ADCs from native antibodies and b) the divinylpyrimidine (DVP) linkers 
developed in this work generate homogeneous and stable ADCs via cysteine re-bridging 
(cross-linking).
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development (Figure 1a). However, the formed succinimide 
thioether is inherently unstable in the body (due to a retro-
Michael reaction) which leads to premature dissociation of the 
payload from the antibody.18,19 The plasma stability of 
maleimide-based linkers has been increased by hydrolysis of 
the succinimide thioether ring through linker modifications or 
antibody engineering.20,21 However, an inherently stable linker 
is preferential. The development of new ADC formats to 
enable site-selective antibody modification, including the 
incorporation of engineered cysteine residues13 and unnatural 
amino acids22,23 into the antibody sequence and the use of 
various enzymatic processes,24–26 have produced ADCs with 
precise DAR and defined attachment points. While effective, 
these methods are complicated and generally inefficient.27 
Recently, disulfide-bridging linkers have emerged for ADC 
production: a bis-reactive linker moiety undergoes reaction 
with both thiol residues derived from a reduced cysteine 
disulfide bond, leading to covalent re-bridging of the protein. 
Such linkers are capable of generating ADCs with more precise 
DAR and drug distribution as well as reforming covalent bonds 
between the antibody chains. Significant progress has been 
made in the field with this class of linker by Baker, Caddick and 
Chudasama and their co-workers, amongst others.27–36 Despite 
these impressive advances, new methods are still required for 
the production of stable and homogeneous ADCs from non-
engineered antibodies. We sought to develop a new disulfide 
bridging linker platform, which generated highly stable ADCs 
with precise DAR and drug distribution. Vinylpyridines have 
previously been used to modify proteins via cysteine 
conjugation.37 Glythera has recently developed a 
monovinylpyridine-based linker platform for ADC construction 
with such conjugates demonstrating excellent stability (Figure 
1a). We envisaged that divinyl-functionalised hetero-aryl 
linkers could be used to achieve cysteine re-bridging, 
generating inherently stable constructs whilst also achieving 
precise control of DAR and site-of-attachment with native 
antibodies.
Herein, we report upon our investigations in this area and 
development of a novel divinylpyrimidine (DVP) linker 
platform for cysteine-bridging bioconjugation with a range of 
proteins (Figure 1b). Model studies using the non-engineered 
trastuzumab antibody validate the utility of this linker platform 
for the generation of highly plasma-stable antibody constructs 
that incorporate different biologically relevant payloads in a 
robust and efficient manner. The utility of the DVP linker 
platform was also exemplified on other protein systems, 
exemplifying the capability of such linkers for a range of 
protein or peptide modification applications.
Results and Discussion
We began our study by identifying the potential of a vinyl-
heteroaryl scaffold for cysteine re-bridging. It was postulated 
that vinylpyridine bioconjugation would be too slow to enable 
efficient cross-linking but that replacement of the pyridine 
with a pyrimidine would enhance the reactivity to desirable 
levels by increasing the electron accepting capacity of the 
heteroaryl ring, without compromising the stability seen with 
vinylpyridine conjugates.38 To test this hypothesis, 
vinylpyrimidine 1 (prepared by a Suzuki-Miyaura cross-
coupling, see Supporting Information) was reacted with Boc-
Cys-OMe in a mixture of aqueous buffer and acetonitrile. 
Pleasingly, full conversion from 1 to conjugate 3 was achieved 
in 15 minutes, monitored by thin layer chromatography (TLC), 
under these bioconjugation compatible conditions (Figure 2a). 
A competition experiment involving the reaction of 1 with Boc-
Cys-OMe and Boc-Lys-OMe at alkaline pH showed full 
conversion to the cysteine conjugate 3. No evidence of the 
lysine conjugate 5 was observed, even with an excess of 
vinylpyrimidine 1 present in the reaction (Figure 2b and ESI 
Figure S1). Similarly, 1 showed poor reactivity with tris(2-
carboxyethyl)phosphine hydrochloride (TCEP), a commonly 
used reducing agent in cysteine bioconjugation (ESI Figure S5), 
demonstrating the capability of this scaffold for 
chemoselective cysteine conjugation. The stability of conjugate 
3 under physiological conditions was investigated by 
incubation with an excess of reduced L-glutathione (GSH) in pH 
7.4 buffer at 37 °C. The stability was tracked via 1H NMR and 
pleasingly, almost no degradation (<5%) was observed after 
two weeks. In comparison, the corresponding maleimide 
conjugate 6 showed >50% conversion to the glutathione-
maleimide conjugate after two weeks under the same 
conditions (Fig. 2c and S6).  This suggested that vinylpyrimidine 
bioconjugation could indeed be used to generate conjugates 
that are stable under physiological conditions. Efforts then 
Figure 2: Development and analysis of the DVP linkers. a) conjugation of 
vinylpyrimidine 1 with N-Boc-Cys-OMe, b) selectivity experiment by reaction of N-
Boc-Cys-OMe and N-Boc-Lys-OMe with an excess of 1, c) stability comparison of 
vinylpyrimidine-conjugate 3 versus maleimide conjugate 6 in the presence of reduced 
GSH and d) DVP linkers 7, 8 and 9.
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turned to the synthesis of divinylpyrimidine (DVP) linkers 
which contained reactive synthetic handles suitable for 
attachment of other modalities, such as drugs or fluorophores. 
To this end, DVP linkers 7, 8 and 9 were synthesised in one, 
two and three steps, respectively (Figure 2d, see ESI for 
synthetic details). The chemoselectivity of linkers 7, 8 and 9 
was then confirmed in an analogous way to 
monovinylpyrimidine 1 (ESI Figures S1-S4). Subsequently, the 
stability of Boc-Cys-OMe modified 7, 8 and 9 in the presence of 
GSH was also demonstrated via 1H NMR (ESI Figure S6).
We next sought to ascertain the reactivity of the DVP 
linkers in protein systems. RadA from Pyrococcus furiosus is a 
DNA recombinase enzyme that does not contain any cysteine 
residues. Through site-directed mutagenesis, a monomeric 
version was produced that contained two cysteine residues in 
close proximity in the tertiary structure (PfRadA-dCys, ESI 
Figure S25). Pleasingly, reduction of the mutant PfRadA with 
TCEP followed by the addition of linkers 7, 8 or 9 (15 equiv.) 
for 1 hour at 37 °C yielded excellent conversion to the desired 
covalently re-bridged conjugates 10, 11 and 12, as detected by 
LC-MS (Figure 3a and ESI Figures S79). To evaluate the 
intended strategy further, the bridging reaction was appraised 
in a system where interchain bridging between two 
polypeptide chains would be required. Antibody Fabs 
(fragment, antigen binding) are heterodimeric proteins with 
the chains linked by a single disulfide. Evaluation of the DVP 
linker platform by reduction of trastuzumab Fab with TCEP, 
followed by reaction with 7, 8 or 9 led to complete conversion 
to the desired interchain-bridged conjugates 13-15 in ~30 
minutes using a slight excess of the linker (10 equiv.) (Figure 
3b and ESI Figures S1013). Kinetic analysis of the bridging rate 
of 8 was conducted with 10 and 20 equivalents linker after 
TCEP reduction. Strikingly, >90% re-bridging of the Fab chains 
was observed for both stoichiometries after only 15 minutes 
(ESI Figure S14). To confirm the selectivity of the DVP linker 
platform for cysteine residues, 8 was incubated with 
unreduced trastuzumab Fab and no reaction was observed 
after two hours at 37 °C (ESI Figure S23). These results 
exemplify the potential for the DVP linker platform to serve as 
a general protein modification tool for monomeric and 
multimeric proteins.
Encouraged by earlier results, efforts shifted toward 
modification of an IgG antibody. DVP linkers potentially enable 
modification of all four interchain disulfides in an IgG1, 
generating an ADC with definitive modification sites while 
giving a consistent DAR of four.39 Trastuzumab mAb was 
    
recombinant PfRadA with DVP linkers 7, 8 and 9 resulted in covalently re-bridged 
conjugates 10, 11 and 12, and b) bridging of trastuzumab Fab with 7, 8 and 9 resulted 
in the desired interchain bridged conjugates 13, 14 and 15. 
   
  
   
   
  
   
   
   
Figure 3: Reaction of trastuzumab with the DVP linkers and subsequent analysis. a) Cysteine bridging of trastuzumab with 7, 8 or 9 resulted in re-bridged 
mAbs 16, 17 and 18, b) analysis of conjugate 16, 17 and 18 by SDS-PAGE; Lane 1 is non-reducing, lanes 2-5 are reducing; Lanes M) molecular weight marker, 
1) trastuzumab, 2) reduced trastuzumab, 3) 16, 4) 17, 5) 18, and c) SEC analysis of 18 
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reduced with TCEP, revealing eight free thiols as evidenced by 
LC-MS and Ellman’s assay (ESI Figure S15). Subsequently, the 
reduced antibody was treated with a slight excess of 7, 8 or 9  
(10 equiv. per disulfide) for two hours at 37 °C (Figure 4a). 
Removal of small molecule reagents by dialysis was followed 
by LC-MS, SDS-PAGE and RP-HPLC analysis. The fully re-bridged 
mAbs 16, 17 and 18 were evident by LC-MS, suggesting good 
conversion to the desired bioconjugates (ESI Figures S15, S17 
and S18). Analysis by SDS-PAGE and RP-HPLC confirmed the 
presence of the correctly bridged antibodies (Figure 4b and ESI 
Figure S17) along with the ‘half-antibody’ formed by intrachain 
bridging of the hinge region heavy chain cysteines, an issue 
seen with other re-bridging linkers.35,40 A large number of 
conditions (reaction concentration, time, linker stoichiometry) 
were explored to avoid this ‘half-antibody’ formation, with 
little change observed (ESI Table S1 and Figure S16). Through 
this process, it was found that the reaction worked efficiently 
(90-95% conversion to the bridged bioconjugates) at low 
concentrations (<10 μM) and with a slight excess of DVP (2.5 
equiv. per disulfide). We postulate that the half-antibody 
conjugate remains useful as the modification site and DAR are 
         
          
chains are always re-bridged efficiently, ensuring that the Fab 
region (the region that confers receptor specificity to the 
antibody) is covalently linked. In order to determine the effect 
of bridging on mAb aggregation, antibody conjugate 18 was 
analysed by size-exclusion chromatography (SEC). This showed 
identical aggregation levels observed for 18 and the 
unmodified mAb (Figure 4c). 
It was anticipated that the synthetic handles present in 
DVP linkers would enable modular and divergent 
functionalisation, both before and after DVP antibody 
conjugation. Terminal alkyne-functionalised DVP 8 was 
identified as a suitable candidate for post-conjugation 
modification, as copper-catalysed azide-alkyne cycloaddition 
(CuAAC) chemistry offers a well-established method for 
diverse functionalisation under physiologically relevant 
conditions.41 An azide-functionalised doxorubicin (19) was 
synthesised and reacted with 18 in the presence of 
CuSO4.5H2O, tris(3-hydroxyprolyltriazolylmethyl)amine 
(THPTA) and sodium ascorbate (Figure 5a). Gratifyingly, 
Figure 5: Functional modification and stability analysis of DVP-modified trastuzumab. a) On-antibody CuAAC reaction between modified 
trastuzumab, 18 forming a doxorubicin conjugate, 21 and an AlexaFluor488 conjugate, 22, b) stability analysis by SDS-PAGE of conjugate 
22 in human plasma supplemented with GSH; P = human plasma, MW = molecular weight marker, days of incubation indicated above the 
representative lane. Left gel is after coomassie staining, right gel is in-gel fluorescence measured before staining, and c) DVP-mediated 
formation of an MMAE ADC, 25.
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excellent conversion to triazole product 21 was observed by 
LC-MS. DAR analysis by UV-vis spectroscopy also confirmed 
high conversion with a measured DAR of 4.0 (ESI Figure S19). 
With the aim of creating a potentially valuable cellular imaging 
agent, conjugate 18 was reacted with AlexaFluor™ 488 azide 
20 under CuAAC conditions (Figure 5a). Similarly, excellent 
conversion was observed with a measured fluorophore-
antibody ratio (FAR) of 3.9 (ESI Figure S20).
Synthesis of 22 enabled assessment of the plasma stability 
of DVP bioconjugates. The fluorescent antibody conjugate was 
incubated in human plasma supplemented with GSH at 37 °C 
for two weeks. Pleasingly, in-gel fluorescence and coomassie 
staining revealed almost no transfer of the AlexaFluor488 
label onto plasma proteins, or release of individual heavy or 
light chains from the antibody (Figure 5b and ESI Figure 22). 
This analysis confirms the stability assessment made on the 
small molecule model system that DVP linkers enable the 
generation of highly stable bioconjugates.
Functionalisation before antibody conjugation was then 
examined using the highly potent dolastatin 10 analogue, 
monomethylauristatin E (MMAE) as a representative payload. 
A DVP-PEG4-MMAE linker-warhead, 24 was prepared from 8 
and azide-functionalised MMAE (23) (see ESI). Reaction of 
reduced trastuzumab with 24 (10 equiv. per disulfide) 
         
    
The biological effects of DVP-bridging were then 
investigated. Firstly, trastuzumab conjugates, 16-18 all 
demonstrated comparable affinities to the native antibody for 
the HER2 receptor via enzyme-linked immunosorbent assay 
(ELISA) (Figure 6a). Fluorescence-activated cell sorting (FACS) 
coupled with live individual cell imaging was next used to 
ensure that the DVP conjugation did not alter cellular 
recognition and selectivity. Fluorescent trastuzumab 
conjugate, 22 was incubated in both HER2-positive (SKBR3 and 
BT474) and HER2-negative (MCF7 and T47D) breast cancer cell 
lines. The cells were incubated at 37 °C for 1 hour to allow 
antigen binding and complex internalisation, followed by 
washing with PBS to remove any unbound antibody. 
Subsequent FACS analysis revealed full labelling of both HER2-
positive cell lines while only minor labelling was observed with 
HER2-negative cell lines (Figure 6b). Internalisation of the 
conjugate was observed in both HER2-positive cell types, with 
no internalisation visible in either HER2-negative cell line 
(Figure 6c), confirming that DVP bridging does not affect 
receptor specificity, affinity or complex internalisation. 
Finally, evaluation of the in vitro cytotoxicity of a 
therapeutically relevant ADC was undertaken. DVP-MMAE ADC 
25, containing a non-cleavable linker was used to treat both 
HER2-positive (SKBR3 and BT474) and HER2-negative (MCF7 
and T47D) cell lines. Cytotoxicity was only observed in the 
HER2-positive cell lines (Figure 6f and ESI Figure S24), 
demonstrating that DVP linkers do not affect the cell-killing 
ability of MMAE, enabling the use of these linkers for the 
delivery of auristatin payloads with non-cleavable linkers. In 
contrast to the specific cytotoxicity observed with our ADC,
treatment of the same cell lines with free MMAE resulted in 
high levels of cytotoxicity in both HER2-positive and HER2-
negative cell lines (Figure 6d). Furthermore, incubation of 
unmodified trastuzumab with these cell lines did not cause 
significant cytotoxicity (Figure 6e).
Conclusion
In conclusion, we have developed a novel DVP linker platform 
for bioconjugation through the covalent re-bridging of cysteine 
residues generated by the reduction of native disulfide bonds. 
Model studies using the trastuzumab antibody validate the 
utility of this linker platform for the efficient generation of 
highly plasma-stable antibody constructs from non-engineered 
antibodies. We have shown that this technology can be used 
to introduce different biologically relevant payloads, in an 
efficient and site-selective manner with control over DAR, 
either before or after bioconjugation, without recourse to any 
other additional processes. Furthermore, the conjugation 
platform utilizes a reaction that is orthogonal to other 
biocompatible reactions (such as the CuAAC), enabling their 
use in tandem with one another.  The modified antibodies 
maintained their cellular specificity and receptor affinity, and a 
DVP-ADC demonstrated exquisite potency and selectivity for 
its target cells, while having little effect on the mechanism of 
Figure 6: Biological evaluation of the DVP linker platform. a) Binding affinity 
comparison of trastuzumab, 16, 17 and 18 via ELISA. Error bars represent the standard 
deviation of biological quadruplicates, b) percentage labelling of HER2-positive and 
HER2-negative cells with 22, c) internalisation of 22 in HER2-positive cells without any 
observed internalisation in HER2-negative cells, and cytotoxicity in HER2-positive and 
HER2-negative cells with d) MMAE, e) trastuzumab and f) DVP-MMAE ADC 25. Viability 
data shows the mean of three independent experiments and error bars represent 
s.e.m.
d
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action of its auristatin payload. In addition, the DVP linkers 
showed excellent cysteine re-bridging of monomeric and 
dimeric proteins, enabling their use for general protein 
modification,42 protein stabilisation43,44 or the development of 
other biotherapeutics such as stapled peptides.45,46
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Divinylpyrimidine (DVP) linkers enable selective protein modification and provide 
access to highly stable and functional antibody-drug conjugates.
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